Genetic variation at the human tissue-type plasminogen activator (tPA) locus: Haplotypes and analysis of association to plasma levels of tPA

European Journal of Human Genetics

Volumn 11, Issue 8, 2003, Pages 603-610

  Ladenvall, P ^a   Nilsson, S ^a,b   Jood, K ^a   Rosengren, A ^a   Blomstrand, C ^a   Jern, Christina ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Haplotype; Plasminogen activator inhibitor; Single nucleotide polymorphism; Tissue type plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHROMOSOME; CONTROLLED STUDY; FEMALE; GENE INSERTION SEQUENCE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HERITABILITY; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN;

BASE SEQUENCE; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TISSUE PLASMINOGEN ACTIVATOR; VARIATION (GENETICS);

INSERTION SEQUENCES; UNIDENTIFIED INSERTION SEQUENCE;

EID: 0042921449     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201011     Document Type: Article

References (43)

1. Wun TC, Capuano A: Spontaneous fibrinolysis in whole human plasma. Identification of tissue activator-related protein as the major plasminogen activator causing spontaneous activity in vitro. J Biol Chem 1985; 260: 5061-5066.
2. Emeis JJ: Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. Ann NY Acad Sci 1992; 667: 249-258.
3. Carmeliet P, Collen D: Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost 1995; 74: 429-436.
4. Matsuno H, Kozawa O, Niwa M, et al: Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost 1999; 81: 601-604.
5. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
6. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
7. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE: Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943.
8. Kooistra T, Schrauwen Y, Arts J, Emeis JJ: Regulation of endothelial cell t-PA synthesis and release. Int J Hematol 1994; 59: 233-255.
9. Degen SJ, Rajput B, Reich E: The human tissue plasminogen activator gene. J Biol Chem 1986; 261: 6972-6985.
10. Henderson BR, Sleigh MJ: TATA box-independent transcription of the human tissue plasminogen activator gene initiates within a sequence conserved in related genes. FEBS Lett 1992; 309: 130-134.
11. Costa M, Shen Y, Maurer F, Medcalf RL: Transcriptional regulation of the tissue-type plasminogen-activator gene in human endothelial cells: identification of nuclear factors that recognise functional elements in the tissue-type plasminogen-activator gene promoter. Eur J Biochem 1998; 258: 123-131.
12. Bulens F, Merchiers P, Ibanez-Tallon I et al: Identification of a multihormone responsive enhancer far upstream from the human tissue-type plasminogen activator gene. J Biol Chem 1997; 272: 663-671.
13. Ladenvall P, Wall U, Jern S, Jern C: Identification of eight novel single-nucleotide polymorphisms at human tissue-type plasminogen activator (t-PA) locus: association with vascular tPA release in vivo. Thromb Haemost 2000; 84: 150-155.
14. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I: Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 96: 761-768.
15. Wilhelmsen L, Johansson S, Rosengren A, Wallin I, Dotevall A, Lappas G: Risk factors for cardiovascular disease during the period 1985-1995 in Goteborg, Sweden. The GOT-MONICA Project. J Intern Med 1997; 242: 199-211.
16. Minnesota code for resting electrocardiograms. in: Rose GA BH, Gillum RF, Prineas RJ (eds): Cardiovascular survey methods. Geneva: World Health Organization, 1982.
17. Ranby M, Nguyen G, Scarabin PY, Samama M: Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay. Thromb Haemost 1989; 61: 409-414.
18. Meijer P, Pollet DE, Wauters J, Kluft C: Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated. Clin Chem 1994; 40: 110-115.
19. de Maat MP, de Bart AC, Hennis BC et al: Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996; 16: 1156-1162.
20. Livak KJ, Marmaro J, Todd JA: Towards fully automated genomewide polymorphism screening. Nat Genet 1995; 9: 341-342.
21. Jern C, Ladenvall P, Wall U, Jern S: Gene polymorphism of t-PA is associated with forearm vascular release rate of t-PA. Arterioscler Thromb Vasc Biol 1999; 19: 454-459.
22. Tjärnlund A, Andersson M, Jood K, Ladenvall P, Jern C: Rapid genotyping of hemostatic gene polymorphisms using the 5′ nuclease assay. Thromb Haemost 2003; 89: 962-968.
23. Lewontin R: The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 1964; 49: 49-67.
24. Terwilliger J, Ott J: Linkage disequilibrium between alleles at marker loci; in: Terwilliger J, Ott J (eds): Handbook of human genetic linkage. Baltimore: John Hopkins University Press, 1994: pp 188-198.
25. Eliasson M, Evrin P, Lundblad D, Asplund K, Ranby M: Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. Fibrinolysis 1993; 7: 316-323.
26. Eliasson M, Evrin PE, Lundblad D: Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol 1994; 47: 513-524.
27. Ridker PM, Vaughan DE, Stampfer MJ, Sacks FM, Hennekens CH: A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I, A-II, and B-100. Arterioscler Thromb 1993; 13: 1587-1592.
28. Juhan-Vague I, Thompson SG, Jespersen J: Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993; 13: 1865-1873.
29. Wall U, Jern C, Bergbrant A, Jern S: Enhanced levels of tissue-type plasminogen activator in borderline hypertension. Hypertension 1995; 26: 796-800.
30. Hooper WC, Lally C, Austin H et al: The role of the t-PA I/D and PAI-1 4G/SG polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res 2000; 99: 223-230.
31. Iacoviello L, di Casteluovo A, de Knijff P, d'Orazio C, Kluft C, Donati M: Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI). Fibrinolysis 1996; 10: 13-16.
32. van der Bom JG, de Knijff P, Haverkate F et al: Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study. Circulation 1997; 95: 2623-2627.
33. Blaxill J, Futers T, Grant P: A novel tissue plasminogen activator promoter polymorphism: functional characteristics and relationship to atheroma and myocardial infarction. Thromb Haemost 2001; 86: abstract.
34. Drysdale CM, McGraw DW, Stack CB et al: Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000; 97: 10483-10488.
35. Souto JC, Almasy L, Borrell M et al: Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101: 1546-1551.
36. de Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ: The genetics of haemostasis: a twin study. Lancet 2001; 357: 101-105.
37. Freeman MS, Mansfield MW, Barrett JH, Grant FJ: Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability. Arterioscler Thromb Vasc Biol 2002; 22: 506-510.
38. Glueck CJ, Glueck HI, Tracy T, Speirs J, Stroop D: Inheritance conjointly contributing to fibrinolysis and hyperlipidemia. Metabolism 1993; 42: 1410-1419.
39. Nakazawa I, Nakajima T, Ishigami T, Umemura S, Emi M: Linkage disequilibrium and haplotype analysis among eight novel single-nucleotide polymorphisms in the human tissue-type plasminogen activator (t-PA) gene. J Hum Genet 2001; 46: 367-371.
40. Henry M, Tregouet DA, Alessi MC et al: Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol 1998; 18: 84-91.
41. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES: High-resolution haplotype structure in the human genome. Nat Genet 2001; 29: 229-232.
42. Tiret L, Poirier O, Nicaud V et al: Heterogeneity of linkage disequilibrium in human genes has implications for association studies of common diseases. Hum Mol Genet 2002; 11: 419-429.
43. Johnson GC, Esposito L, Barratt BJ et al: Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29: 233-237.